Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The incidence of cancer in the small intestine is considerably lower than the incidence of cancer in the large intestine. Why might this be? This article suggests that the microbiota might be part of the explanation for this difference.
Eswarappaet al. have identified a novel anti-angiogenic form of vascular endothelial growth factor A (VEGFA) that is produced by programmed translational readthrough.
Two recent papers have identified pathways by which malignant cells, or the therapy used to treat them, can influence the bone marrow niche to promote progression of haematopoietic malignancies.
This Review discusses the role of the tumour microenvironment in the pathogenesis of B cell lymphomas, proposing three main types of lymphoma-associated tumour microenvironment.
Non-small-cell lung cancers (NSCLCs) are now appreciated to be a group of heterogeneous diseases. This Review discusses the biology of NSCLCs and what we know about their origins, diversity and the microenvironments surrounding them, with a view towards improving therapies.
Recent advances in understanding the biology of senescent cells, especially the secretory phenotypes and the role of immune cell clearance of senescent cells, has revealed more about the role of senescence induction in tumorigenesis and tumour progression. This includes the surprising findings that senescence may promote tumour growth in some contexts.
Oncolytic viruses were originally designed as tumour-lysing therapeutics. However, they also initiate systemic antitumour immune responses. Can these viruses be exploited to enhance antitumour immune responses, and how might they be combined with other cancer immunotherapies?
This Opinion article highlights the similarities in the pathways involved in induced pluripotent stem cell (iPSC) generation and tumorigenesis. The authors hope that collaboration between researchers working with iPSCs and cancer cells will facilitate progress towards safe and effective regenerative medicine, as well as more effective targeted cancer therapy.
